Last Updated: November 22, 2026

ZEPATIER Drug Patent Profile

« Back to Dashboard


When do Zepatier patents expire, and what generic alternatives are available?

Zepatier is a drug marketed by Msd Sub Merck and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in ZEPATIER is elbasvir; grazoprevir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the elbasvir; grazoprevir profile page.

DrugPatentWatch® Generic Entry Outlook for Zepatier

Zepatier was eligible for patent challenges on January 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 24, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZEPATIER?
  • What are the global sales for ZEPATIER?
  • What is Average Wholesale Price for ZEPATIER?
Summary for ZEPATIER
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZEPATIER
Generic Entry Date for ZEPATIER*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEPATIER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaPhase 4
Radboud UniversityPhase 1
Hepatitis C TrustPhase 4

See all ZEPATIER clinical trials

US Patents and Regulatory Information for ZEPATIER

ZEPATIER is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZEPATIER is ⤷  Start Trial.

This potential generic entry date is based on patent 7,973,040.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 DISCN Yes No 8,871,759 ⤷  Start Trial Y Y ⤷  Start Trial
Msd Sub Merck ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 DISCN Yes No 7,973,040 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ZEPATIER

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Merck Sharp & Dohme B.V. Zepatier elbasvir, grazoprevir EMEA/H/C/004126ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. Authorised no no no 2016-07-22
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ZEPATIER

When does loss-of-exclusivity occur for ZEPATIER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2588
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 09274190
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 0916235
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 31177
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 11000145
Estimated Expiration: ⤷  Start Trial

China

Patent: 2159285
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 51757
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 110089
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0120866
Estimated Expiration: ⤷  Start Trial

Patent: 0140693
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 13752
Estimated Expiration: ⤷  Start Trial

Patent: 15503
Estimated Expiration: ⤷  Start Trial

Patent: 17005
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 10095
Estimated Expiration: ⤷  Start Trial

Patent: 40350
Estimated Expiration: ⤷  Start Trial

Dominican Republic

Patent: 011000023
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 11010777
Estimated Expiration: ⤷  Start Trial

El Salvador

Patent: 11003813
Patent: COMPUESTOS MACROCICLICOS DE QUINOXALINA COMO INHIBIDORES DE LA PROTEASA NS3 DE HCV
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 9327
Estimated Expiration: ⤷  Start Trial

Patent: 1170241
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 10095
Estimated Expiration: ⤷  Start Trial

Patent: 40349
Estimated Expiration: ⤷  Start Trial

Patent: 40350
Estimated Expiration: ⤷  Start Trial

France

Patent: C1027
Estimated Expiration: ⤷  Start Trial

Honduras

Patent: 11000209
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 73402
Estimated Expiration: ⤷  Start Trial

Patent: 73403
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 700001
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 0580
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 20797
Estimated Expiration: ⤷  Start Trial

Patent: 11528713
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 310095
Estimated Expiration: ⤷  Start Trial

Patent: 2016049
Estimated Expiration: ⤷  Start Trial

Luxembourg

Patent: 0002
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 2070
Patent: MACROCYCLIC QUINXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 11000826
Estimated Expiration: ⤷  Start Trial

Montenegro

Patent: 024
Estimated Expiration: ⤷  Start Trial

Patent: 132
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 502
Estimated Expiration: ⤷  Start Trial

Netherlands

Patent: 0857
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 0638
Patent: MACROCYCLIC QUINOXALINE COMPOUNDS AS Hepatitis C Virus NS3 PROTEASE INHIBITORS
Estimated Expiration: ⤷  Start Trial

Nicaragua

Patent: 1100023
Patent: COMPUESTOS MACROCÍCLICOS DE QUINOXALINA COMO INHIBIDORES DE LA PROTEASA NS3 DE VHC.
Estimated Expiration: ⤷  Start Trial

Norway

Patent: 17004
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 110212
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 10095
Estimated Expiration: ⤷  Start Trial

Patent: 40350
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 10095
Estimated Expiration: ⤷  Start Trial

Patent: 40350
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 534
Patent: MAKROCIKLIČNA JEDINJENJA HINOKSALINA KAO INHIBITORI HCV NS3 PROTEAZE (MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS)
Estimated Expiration: ⤷  Start Trial

Patent: 420
Patent: KOMBINACIJE MAKROCIKLIČNOG JEDINJENJA HINOKSALINA KOJE JE INHIBITOR HCV NS3 PROTEAZE SA DRUGIM HCV SREDSTVIMA (COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS)
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 10095
Estimated Expiration: ⤷  Start Trial

Patent: 40350
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1313675
Estimated Expiration: ⤷  Start Trial

Patent: 110036627
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 92611
Estimated Expiration: ⤷  Start Trial

Patent: 91090
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1023860
Patent: Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Estimated Expiration: ⤷  Start Trial

Patent: 41638
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 11000014
Patent: MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 0436
Patent: MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEPATIER around the world.

Country Patent Number Title Estimated Expiration
Argentina 072588 ⤷  Start Trial
Australia 2009274190 ⤷  Start Trial
Brazil PI0916235 ⤷  Start Trial
Canada 2731177 ⤷  Start Trial
Chile 2011000145 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZEPATIER

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2310095 300857 Netherlands ⤷  Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
2310095 CA 2016 00070 Denmark ⤷  Start Trial PRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
2310095 PA2016049 Lithuania ⤷  Start Trial PRODUCT NAME: GRAZOPREVIRAS ARBA JO FARMACISKAI PRIIMTINOS DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
2410844 300858 Netherlands ⤷  Start Trial DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
2410844 CA 2016 00069 Denmark ⤷  Start Trial PRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Zepatier Market Dynamics, Financial Trajectory, Patent Estate, and Generic Entry Risk

Last updated: October 19, 2026

Zepatier, Merck’s once-daily fixed-dose combination of elbasvir and grazoprevir, entered the hepatitis C market in 2016 with strong pricing and broad genotype coverage. Its commercial position deteriorated rapidly as competing direct-acting antivirals became cheaper, shorter-course therapies and hepatitis C treatment volumes shifted toward public programs and generic procurement. Zepatier remains FDA-approved, but its financial contribution is now immaterial to Merck relative to Keytruda, Gardasil, Winrevair, and other growth products.

The main commercial risks are market contraction, payer price pressure, treatment prioritization, and generic competition. Biosimilar risk is not relevant because Zepatier is a chemically synthesized small-molecule drug, not a biologic.

What is Zepatier and how does it work?

Zepatier is an oral fixed-dose tablet containing 50 mg of elbasvir and 100 mg of grazoprevir. It is indicated for chronic hepatitis C virus infection caused by genotypes 1 or 4 in adults and, under the current FDA label, in pediatric patients aged 12 years and older weighing at least 30 kilograms [1].

Product attribute Zepatier
Active ingredients Elbasvir and grazoprevir
Drug class Direct-acting antiviral
Form Once-daily oral tablet
Manufacturer Merck Sharp & Dohme Corp.
FDA approval January 28, 2016
Primary targets NS5A and NS3/4A proteins
Principal genotypes HCV genotypes 1 and 4
Typical treatment duration 12 weeks in many patients; longer or ribavirin-containing regimens in selected cases
Regulatory category Small-molecule prescription drug
Biosimilar pathway Not applicable

Elbasvir inhibits the HCV NS5A replication complex. Grazoprevir inhibits the NS3/4A protease. Resistance-associated substitutions, baseline viral genotype, prior treatment, cirrhosis status, and renal function affect regimen selection.

Zepatier was commercially differentiated by its once-daily dosing and use in patients with chronic kidney disease, including patients with severe renal impairment. Its genotype coverage was narrower than some competing products, particularly after pan-genotypic regimens became standard.

When did Zepatier lose market exclusivity?

Zepatier lost practical market exclusivity before the expiration of every listed patent because its clinical and commercial value declined as competing HCV therapies displaced it.

The product launched during a crowded HCV market that included Sovaldi, Harvoni, Viekira Pak, Epclusa, Mavyret, and later generic or authorized-generic alternatives. Gilead’s Epclusa and AbbVie’s Mavyret expanded treatment across more genotypes, simplified treatment selection, and applied substantial price pressure.

Zepatier exclusivity timeline

Date Event Commercial effect
January 2016 FDA approves Zepatier Entry into the HCV direct-acting antiviral market
2016 U.S. launch Initial access agreements and payer contracting
2017 Pediatric and label-related expansion Broader eligible population
2017-2019 Mavyret and other pan-genotypic regimens gain adoption Lower differentiation for Zepatier
2019 onward HCV treatment shifts toward lower-cost procurement Declining realized price and prescription volume
2020-2023 Merck reports sharply reduced Zepatier sales Product becomes a small commercial asset
2024 onward Generic and procurement competition remains the principal risk Limited upside absent a new indication or pricing event

The FDA granted Zepatier five years of new chemical entity exclusivity beginning with approval. That period expired in 2021. Any pediatric exclusivity associated with later labeling would have extended applicable regulatory protection by six months, but it would not have restored the product’s former commercial position.

What patents protect Zepatier?

Zepatier is protected by patents covering the active ingredients, related chemical compounds, pharmaceutical compositions, and aspects of treatment. The most important U.S. patents are associated with elbasvir and grazoprevir compound technology developed within Merck’s HCV research programs.

The Orange Book must be used to determine the patents formally listed for the approved product and their applicable expiration dates. Patent-term adjustment, patent-term extension, pediatric exclusivity, and changes in Orange Book listings can affect the operative date for ANDA litigation.

Key patent categories

Patent category Protected subject matter Commercial relevance
Compound patents Elbasvir, grazoprevir, and related chemical structures Core active-ingredient protection
Pharmaceutical composition patents Combinations and dosage forms Potential protection for the fixed-dose tablet
Method-of-use patents Treatment of specified HCV genotypes or patient populations May create residual litigation risk
Crystalline or solid-state patents Salt, polymorph, or formulation characteristics Can complicate generic development
Process patents Manufacturing and purification methods Usually weaker against a non-infringing manufacturing route

The principal patent risk does not arise from a single expiration date. It depends on which patents are listed for the reference drug, which claims are asserted, whether a generic applicant makes a Paragraph IV certification, and whether the generic can obtain a judgment of invalidity, unenforceability, or non-infringement.

What is the Orange Book status of Zepatier?

Zepatier is listed in the FDA Orange Book as a prescription drug with an approved new drug application held by Merck Sharp & Dohme Corp. The Orange Book identifies patent information submitted by the NDA holder and any applicable pediatric exclusivity.

Orange Book status is not equivalent to complete market exclusivity. A listed patent can be challenged, designed around, invalidated, or rendered commercially less important by the narrow remaining market. Conversely, a formulation or method-of-use patent can delay an ANDA launch if it supports a timely infringement action.

For Zepatier, the most material Orange Book questions are:

  1. Which compound and composition patents remain listed?
  2. Which patent claims cover the approved fixed-dose combination rather than only an individual active ingredient?
  3. Has any pediatric exclusivity period expired?
  4. Have generic applicants filed Paragraph IV certifications?
  5. Has Merck initiated patent litigation within the statutory 45-day period?

Which companies are challenging Zepatier?

Publicly visible generic competition is more important than branded competition at this stage. Generic applicants may seek approval for elbasvir/grazoprevir tablets through the ANDA pathway, subject to patent certifications and any litigation initiated by Merck.

The competitive set includes:

  • Generic manufacturers developing elbasvir/grazoprevir tablets.
  • AbbVie with Mavyret, a pan-genotypic direct-acting antiviral.
  • Gilead with Epclusa and other HCV products.
  • Public-sector procurement programs using lower-cost alternatives.
  • Treatment providers selecting regimens based on genotype breadth, duration, renal suitability, and net price.

A meaningful Paragraph IV challenge would be commercially significant only if the generic applicant could manufacture at scale and obtain access through Medicaid, correctional-health systems, Veterans Affairs, and other institutional channels. Patent victory alone would not guarantee substantial sales.

What patent litigation affects Zepatier?

Zepatier’s litigation exposure is lower than during the product’s launch period because the market has contracted and the product has limited remaining revenue potential. The principal litigation scenario is an ANDA suit following a Paragraph IV certification.

Generic litigation sequence

Stage Legal event Practical consequence
1 ANDA applicant files with Paragraph IV certification Applicant alleges that listed patents are invalid, unenforceable, or not infringed
2 NDA holder receives notice Merck has 45 days to file an infringement action
3 Timely suit is filed FDA approval may be stayed for up to 30 months, subject to statutory exceptions
4 Court resolves patent claims or parties settle Generic entry may be blocked, delayed, or permitted
5 Generic launches Price compression and channel substitution follow

A patent settlement could include a licensed entry date, an authorized generic arrangement, supply terms, or restrictions tied to patent claims. No settlement should be treated as evidence of patent validity unless its terms and court record support that conclusion.

How strong is the Zepatier patent estate?

Zepatier has a technically meaningful patent estate but a weaker commercial position than its original patent life suggests.

Strengths

  • Compound patents can create a high barrier if valid and enforceable.
  • The product combines two active ingredients, increasing manufacturing and regulatory complexity.
  • HCV antiviral patents often cover stereochemically complex compounds and challenging synthetic routes.
  • Renal-use positioning provides clinical differentiation in a limited population.

Weaknesses

  • The product’s approved genotype coverage is narrower than pan-genotypic alternatives.
  • HCV treatment is highly price-sensitive.
  • Generic applicants can target the active ingredients separately or develop non-infringing manufacturing processes.
  • Method-of-use claims may have limited value if doctors and payers use broader treatment protocols.
  • Low remaining sales reduce the economic value of prolonged litigation.

Patent strength should therefore be measured by expected cash-flow protection, not only claim breadth. A patent that can delay entry but protect only a declining revenue stream may have limited negotiating value.

What is Zepatier’s financial trajectory?

Zepatier generated substantial early sales but declined as the HCV market matured. Merck’s financial reporting shows the pattern of a launch-period antiviral moving into a declining or residual-product category.

Commercial trajectory

Period Market condition Zepatier implication
2016 High HCV treatment demand and premium pricing Rapid launch uptake
2017 Strong competition and payer contracting Sales growth became dependent on net price and access
2018-2019 Mavyret and pan-genotypic therapies gained share Volume and pricing weakened
2020-2021 Pandemic disruption and lower treatment initiation Further erosion
2022 onward Mature market and institutional price pressure Limited branded growth potential

Merck’s annual reports identify Zepatier among products affected by lower demand and HCV market conditions. The company has increasingly emphasized its oncology, vaccines, immunology, and hospital businesses rather than Zepatier [2-5].

Revenue exposure

Zepatier’s revenue exposure is now small relative to Merck’s total sales. A generic launch would have a negligible effect on Merck’s consolidated financial statements but could eliminate much of the product’s remaining revenue.

For a potential acquirer or licensing partner, the relevant valuation variables are:

  • Net sales by channel rather than list price.
  • Government and institutional tender exposure.
  • Remaining patent life.
  • Cost of goods for the two-active-ingredient tablet.
  • Inventory and supply obligations.
  • Probability and timing of generic entry.
  • Residual demand among patients with renal impairment or limited alternative options.

What generic launch scenarios exist for Zepatier?

Scenario 1: No near-term generic entry

Merck retains the remaining branded business, but sales continue to decline as prescribers favor pan-genotypic products and payers seek lower prices.

Scenario 2: Authorized or licensed generic entry

Merck or a partner permits an earlier launch while preserving some economics through supply, royalty, or channel arrangements. Branded sales decline, but Merck may retain manufacturing or licensing revenue.

Scenario 3: First independent generic launch

A successful ANDA launch would cause rapid price erosion. Institutional purchasers would likely switch quickly if the generic is therapeutically equivalent and available in sufficient volume.

Scenario 4: Multiple-generic market

Several suppliers enter after patent barriers fall. Prices compress further, supply reliability becomes more important, and Zepatier becomes a low-margin procurement product.

How does Zepatier compare with Mavyret and Epclusa?

Attribute Zepatier Mavyret Epclusa
Companies Merck AbbVie Gilead
Active ingredients Elbasvir/grazoprevir Glecaprevir/pibrentasvir Sofosbuvir/velpatasvir
Dosing Once daily Once daily, generally three tablets Once daily
Genotype positioning Primarily genotypes 1 and 4 Pan-genotypic Pan-genotypic
Key differentiation Renal-use profile and established efficacy Broad coverage and strong price positioning Broad coverage and extensive clinical adoption
Commercial status Mature, declining Major HCV product Mature, declining but broadly established
Generic risk Increasing Increasing over time Increasing over time
Biosimilar risk None None None

Zepatier’s main disadvantage is not dosing convenience. It is narrower market coverage and reduced relevance in treatment algorithms that favor pan-genotypic therapy.

What is the FDA regulatory status of Zepatier?

Zepatier remains FDA-approved for eligible patients with chronic HCV infection. Its regulatory status does not indicate strong commercial demand. The label continues to impose clinically important conditions, including drug-interaction management, hepatic monitoring, and genotype-specific treatment considerations [1].

The product is subject to the standard regulatory framework for small-molecule drugs:

  • ANDA approval for therapeutically equivalent generics.
  • Paragraph IV patent certifications.
  • Potential 30-month litigation stay.
  • Label carve-outs for patented methods of use.
  • Postmarketing safety and labeling obligations.

Because Zepatier is not a biologic, biosimilar applications under the Public Health Service Act do not apply.

What licensing and partnership factors affect Zepatier?

Merck’s commercial strategy for Zepatier has included payer contracting and access arrangements typical of the HCV market. The economics of any future licensing deal would be shaped by declining demand, procurement concentration, and patent timing rather than by premium branded growth.

Potential transaction structures include:

  • Regional commercialization rights.
  • Generic or authorized-generic licensing.
  • Supply agreements for elbasvir and grazoprevir.
  • Institutional tender partnerships.
  • Rights in countries where patent terms or reimbursement differ.
  • Manufacturing technology licenses.

Geographic value is uneven. High-income markets have largely moved toward pan-genotypic products and aggressive price competition. Lower- and middle-income markets may have demand where Zepatier has procurement approval, but tender pricing and local regulatory requirements constrain margins.

Key Takeaways

  • Zepatier is Merck’s elbasvir/grazoprevir fixed-dose HCV tablet, approved by the FDA in 2016.
  • Its commercial decline reflects HCV market maturity, pan-genotypic competition, payer discounts, and lower treatment volumes.
  • The product remains FDA-approved but has limited strategic importance to Merck’s consolidated business.
  • Biosimilar risk does not apply because Zepatier is a small-molecule drug.
  • Generic entry through the ANDA pathway is the principal remaining exclusivity risk.
  • Compound, composition, method-of-use, and manufacturing patents must be assessed together.
  • A generic launch would likely produce rapid price erosion but little material impact on Merck’s overall revenue.
  • Mavyret and Epclusa have stronger pan-genotypic positioning and displaced Zepatier in many treatment settings.
  • Any licensing value is more likely to arise from regional access, supply, or generic arrangements than from branded growth.

FAQs

Does Zepatier still have market exclusivity?

Zepatier’s five-year new chemical entity exclusivity expired in 2021. Residual patent rights, pediatric exclusivity, and Orange Book-listed patents determine the remaining legal barriers to generic approval.

Can a generic manufacturer make elbasvir and grazoprevir?

Yes. A manufacturer can pursue an ANDA for an equivalent fixed-dose combination, subject to FDA requirements and applicable patent certifications.

Is Zepatier a biologic or biosimilar product?

No. Zepatier is a chemically synthesized small-molecule drug. Biosimilar regulation does not apply.

Why did Mavyret reduce Zepatier sales?

Mavyret offered pan-genotypic coverage, competitive treatment duration, and strong payer positioning. Those attributes reduced the need to select a genotype-specific regimen such as Zepatier.

Does Zepatier remain important for patients with kidney disease?

Zepatier retains clinical relevance for selected patients with severe renal impairment, but treatment decisions depend on current guidelines, drug interactions, genotype, cirrhosis status, and available alternatives.

References

  1. U.S. Food and Drug Administration. (2024). Zepatier prescribing information. Merck Sharp & Dohme Corp. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208261s017lbl.pdf

  2. Merck & Co., Inc. (2017). 2016 annual report. https://www.merck.com/annual-reports/

  3. Merck & Co., Inc. (2019). 2018 annual report. https://www.merck.com/annual-reports/

  4. Merck & Co., Inc. (2022). 2021 annual report. https://www.merck.com/annual-reports/

  5. Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com/annual-reports/

  6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

  7. U.S. Food and Drug Administration. (2024). Hatch-Waxman exclusivity and patent certification provisions. https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/hatch-waxman-amendments-questions-and-answers-consumer-related-issues

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.